Innovative Therapeutics in Oncology and Neuroscience
Significant Achievements in 2023
600 COMMERCIAL EXCELLENCE
00
PIPELINE / PRODUCT PROGRESS
FY 2023 revenues grew 25% Y/Y; 31% Y/Y (CER*)
-
NRDL related sales rebates: $13.0M in 2023 vs.
$5.3M in 2022
VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial
Once-daily oral
Zejula
niraparib
XOPTUNE
GIO™
QINLOCK
(ripretinib) 50 mg tablets
NUZYRA®
(omadacycline)
Approval, launch and NRDL listing
Strong pre-NRDL launch w/ top hospitals
Leading PARPI in OC in China1
40+% volume sold supported by SIP 2
NRDL listings w/ NUZYRA oral form
added in '24
✓ Three NDA acceptances in China
SC efgartigimod (gMG)
SUL-DUR (ABC)³
Repotrectinib (ROS1+ NSCLC)
✓ Positive pivotal data readouts
SC efgartigimod (CIDP)
KarXT (schizophrenia)
TTFields (2L+ NSCLC)
TIVDAK (2L+ CC)
✓ Global pipeline
ZL-1310 (DLL3 ADC) Ph 1 initiated
ZL-1218 (CCR8) Ph 1 initiated
ZL-1102 (IL-17) Ph 2 initiating
4
Abbreviations: New Drug Application (NDA), sulbactam-durlobactam (SUL-DUR), Tumor Treating Fields (TTFields), acinetobacter baumannii-calcoaceticus complex (ABC), subcutaneous (SC), non-small cell lung cancer (NSCLC), chronic inflammatory
demyelinating polyradiculoneuropathy (CIDP), cervical cancer (CC), antibody-drug conjugate (ADC), ovarian cancer (OC), generalized myasthenia gravis (gMG), supplemental insurance plan (SIP), year-over-year (Y/Y), constant exchange rates (CER),
China's national reimbursement drug list (NRDL).
Notes: *Non-GAAP measures. (1) Based on IQVIA 4Q 2023 data and Company analysis, December 2023; (2) Supplemental Insurance Plan (SIP) is the regional customized commercial health insurance plans guided by provincial or municipal
governments; (3) hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.
zaiLabView entire presentation